Search

Displaying results 1391 - 1400 of 10000 in total
  1. Target

    Tyrosine-protein phosphatase non-receptor type 11

    go.drugbank.com/bio_entities/BE0001071
    TargetHumans

    Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus (PubMed:10655584, PubMed:14739280, PubMed:18559669, PubMed:18829466, PubMed:26742...

    Polypeptides: Tyrosine-protein phosphatase non-receptor type 11
  2. Target

    Non-selective voltage-gated ion channel VDAC1

    go.drugbank.com/bio_entities/BE0002468
    TargetHumans

    Non-selective voltage-gated ion channel that mediates the transport of anions and cations through the mitochondrion outer membrane and plasma membrane (PubMed:10661876, PubMed:11845315, PubMed:18755977

    Polypeptides: Non-selective voltage-gated ion channel VDAC1
  3. Target

    Tyrosine-protein phosphatase non-receptor type 2

    go.drugbank.com/bio_entities/BE0012706
    TargetHumans

    Non-receptor type tyrosine-specific phosphatase that dephosphorylates receptor protein tyrosine kinases including INSR, EGFR, CSF1R, PDGFR. … Also dephosphorylates non-receptor protein tyrosine kinases like JAK1, JAK2, JAK3, Src family kinases, STAT1, STAT3 and STAT6 either in the nucleus or the cytoplasm.

    Polypeptides: Tyrosine-protein phosphatase non-receptor type 2
  4. Drug

    Pilocarpine

    go.drugbank.com/drugs/DB01085
    ApprovedInvestigational

    [A262036] Pilocarpine is used to treat dry mouth and various ophthalmic conditions, including elevated intraocular pressure and glaucoma. The usage of glaucoma by pilocarpine dates back to 1875. … [A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors.

  5. Drug

    Rosiglitazone

    go.drugbank.com/drugs/DB00412
    ApprovedInvestigational

    Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. … Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele.

  6. Drug

    Leucovorin

    go.drugbank.com/drugs/DB00650
    ApprovedInvestigational

    [L56092, A257419] Unlike folic acid, leucovorin does not require the enzyme dihydrofolate reductase (DHFR) for activation, allowing it to function even when DHFR is inhibited by drugs like methotrexate … -fluorouracil (5-FU) to enhance therapeutic efficacy in the palliative treatment of advanced colorectal cancer and to treat megaloblastic anemias resulting from folate deficiency when oral therapy is not

    Synonyms: N5-Formyltetrahydrofolic acid, N5-Formyl-5,6,7,8-tetrahydrofolic acid
  7. Drug

    Alectinib

    go.drugbank.com/drugs/DB11363
    ApprovedInvestigational

    It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC … Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance

  8. Drug

    Quercus alba pollen

    go.drugbank.com/drugs/DB10376
    Approved

    Quercus alba pollen, or oak white pollen, is a non-standardized allergen extract used for the diagnosis and treatment of allergic disease to grass pollen.

    Mixtures: 5-oak Mix, Blackjack/bur/post/red/white PollenCategories: Non-Standardized Pollen Allergenic Extract
  9. Drug

    Tolbutamide

    go.drugbank.com/drugs/DB01124
    Approved

    Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin

    Synonyms: N-n-Butyl-N'-tosylurea, N-(Sulfonyl-p-methylbenzene)-N'-N-butylurea
  10. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment.

    Synonyms: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate